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abstract
PURPOSE To describe the first year results of Rwanda’s Screen, Notify, See, and Treat cervical cancer screening
program, including challenges encountered and revisions made to improve service delivery.
METHODS Through public radio broadcasts, meetings of local leaders, church networks, and local women’s
groups, public awareness of cervical cancer screening opportunities was increased and community health
workers were enlisted to recruit and inform eligible women of the locations and dates on which services would be
available. Screening was performed using human papillomavirus (HPV) DNA testing technology, followed by
visual inspection with acetic acid (VIA), and cryotherapy, biopsy, and surgical treatment for those who tested
HPV-positive. These services were provided by five district hospitals and 15 health centers to HIV-negative
women of age 35-45 and HIV-positive women of age 30-50. Service utilization data were collected from the
program’s initiation in September 2013 to October 2014.
RESULTS Of 7,520 cervical samples tested, 874 (11.6%) screened HPV-positive, leading 780 (89%)
patients to undergo VIA. Cervical lesions were found in 204 patients (26.2%) during VIA; of these, 151 were
treated with cryoablation and 15 were referred for biopsies. Eight patients underwent complete hyster-
ectomy to treat advanced cervical cancer. Challenges to service delivery included recruitment of eligible
patients, patient loss to follow-up, maintaining HIV status confidentiality, and efficient use of consumable
resources.
CONCLUSION Providing cervical cancer screening services through public health facilities is a feasible and
valuable component of comprehensive women’s health care in resource-limited settings. Special caution is
warranted in ensuring proper adherence to follow-up and maintaining patient confidentiality.
JCO Global Oncol 7:632-638. © 2021 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Cervical cancer is the leading cause of oncologic
morbidity and mortality among women across sub-
Saharan Africa, including Rwanda.1 Cervical cancer
disproportionately affects low- and middle-income
countries (LMICs): 85% of cases are estimated to
occur in developing regions, with 17% of cases in sub-
Saharan Africa alone.2–4 Because of large and growing
disparities in access to preventive, screening, and
curative services, LMICs are expected to bear 70% of
global mortality because of cervical cancer by 2030.5,6
In Rwanda, cervical cancer accounts for 28.8% of all
cancer diagnoses in women.1 Alarmingly, over the past
30 years, cervical cancer incidence appears to have
increased in all regions of the world except for high-
income countries.4
In 2011, Rwanda made an important first step in
reducing cervical cancer incidence and mortality by
developing a successful, nationwide school-based
human papillomavirus (HPV) vaccination program. In
the first year of the program, 93.2% of girls in their sixth
year of primary school were fully vaccinated for HPV
with Gardasil, a quadrivalent HPV vaccine manufac-
tured by Merck & Co (New York, NY).7 The program
achieved further success in 2012 by reaching 96.6% of
the target population after a catch-up period.8
In 2013-2014, baseline data on HPV prevalence were
determined among a sample of 2,508 women of age
18-69 in Kigali.9 High-risk (HR) HPV strains were
found in 22%,9 a higher prevalence compared with
other countries with high rates of cervical cancer, such
as India (12%)10 and Columbia (10%); this confirmed
the epidemiological imperative for a comprehensive
screening program in Rwanda.11 Several prevalence
studies in Rwanda have confirmed that HR HPV
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women and decreases less with age compared with HIV-
negative women.12–14
Rwanda’s comprehensive cervical cancer program ex-
panded again in 2013, through a partnership with Qiagen
(Hilden, Germany), which supported the introduction and
set-up of cervical cancer screening facilities at five district
hospitals and 15 health centers.8 However, the program
was discontinued in the following year because of the cost
of the test. In this article, the results from the first 12months
of Rwanda’s cervical cancer screening program are pre-
sented along with discussion of implementation challenges
and the potential for renewed scale-up.
METHODS
Program Preparation
In March 2013, the Ministry of Health (MoH) convened a
Technical Working Group composed of representatives
from the Maternal and Child Health, Non-Communicable
Diseases, and HIV and STIs (sexually transmitted infec-
tions) Divisions, Health Communication Center, clinical
services, and the National Reference Laboratory. Planning
was headed by the MoH and the Rwanda Biomedical
Center along with the WHO, Partners in Health, and the
Centers for Disease Control and Prevention.7–9 In keeping
with the values of decentralization and rights-based service
delivery, this Working Group’s first priority was to engage
stakeholders from a variety of backgrounds for guidance
and support for the program’s development. MoH officials,
Directors of District Hospitals, heads of health centers, civil
society groups involved in cancer-related causes, and com-
munity leaders (particularly those representing women’s
groups) were invited to contribute guidance for the program
during workshops and planning sessions. This process of
consultation and collaborative program design ensured that
insights from diverse perspectives were considered and that
future stakeholders were invested in the program’s success
from its inception.
Following these discussions, a thorough situation analysis
was conducted to determine the burden of cervical cancer
disease in Rwanda and to inform decisions regarding the
feasibility and scope of a comprehensive cervical cancer
program. The Non-Communicable Disease Technical
Working Group at MoH undertook a survey of existing
services and resources that could be adapted for cervical
cancer screening and determined whether required ele-
ments could reasonably be acquired or developed. Several
pre-existing components of the Rwandan health system
were well-positioned to accommodate cervical cancer
screening: the nation’s robust network of approximately
45,000 community health workers (CHWs) could be used
to recruit eligible women and ensure appropriate follow-up,
and well-established primary healthcare delivery strategies
could be expanded to make screening available at the local
level.
Screening Strategy
To provide appropriate care to all women, a step-wise
screening and treatment strategy that combines testing
for HPV DNA, visual inspection with acetic acid (VIA),
cryotherapy, biopsy, and surgical treatment was adopted.8
Screening services were offered to all women of age 35-45
and to HIV-positive women of age 30-50. The wider age
range for HIV-positive women was initially implemented
because of the increased risk of precancerous cervical
lesions and a more rapid progression to cancer among HIV-
infected women. However, during the implementation
phase, the risk of unintended disclosure of HIV status was
observed and it was agreed to expand screening to the
wider age range for all women. Figure 1 presents Rwanda’s
algorithm for cervical cancer screening and follow-up
services. In accordance with this Screen, Notify, See,
and Treat model of care delivery, all women are screened
for HPV using the Qiagen careHPV test technology. This
particular HPV test was chosen because of the opportunity
of the MoH to partner with Qiagen. Furthermore, careHPV
is cost effective, easy to use in remote settings, does not
require complex laboratory equipment, and tests for 14 HR
HPV types.15–20 Those who test HPV-positive undergo VIA
to assess for the presence of cervical lesions, which, if
CONTEXT
Key Objective
What is the feasibility of a human papillomavirus testing screening program for the prevention of cervical cancer in Rwanda?
Knowledge Generated
Rwanda’s Screen, Notify, See, and Treat program, conducted in 2013, was effective and feasible despite challenges in
maintaining patient follow-up and achieving efficient use of consumable resources. Existing primary healthcare delivery
structures and networks of community health workers in Rwanda were successfully leveraged in the screening program.
Relevance
Given recent changes in WHO recommendations, this program should be reinstated with revisions that address the challenges
identified in order to reach global goals of cervical cancer elimination. A robust human papillomavirus screening program could be
more appropriate in reducing the burden of cervical cancer than the existing widespread use of visual inspection with acetic acid.
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present, are treated via cryotherapy or biopsied for further
evaluation. Women with biopsies indicative of cervical
cancer that cannot be treated by cryotherapy (large pre-
cancerous lesions or lesions in the endocervical canal) are
referred for surgical management, either by loop electro-
surgical excision procedure or complete hysterectomy.
Women who test HPV-negative do not undergo VIA but are
rescreened for HPV after 7 years if they areHIV-negative, or 3
years if HIV-positive. Women who are HPV-positive but VIA-
negative are rescreened in 1 year, regardless of HPV ge-
notype. The slow development of precancerous lesions into
invasive cervical cancer allows for this extended screening
interval.21 Village level recruitment by CHWs for screening
activities ensures that patients return at the necessary in-
tervals for future screening and/or follow-up visits.
In May 2013, training curricula for the Screen, Notify, See,
and Treat model were delivered to health professionals at
five district hospitals and 15 health centers, which were
selected on the basis of service delivery capacity, regional
representation, and availability of comprehensive cancer
care. One medical doctor per district hospital, two nurses
per health center, and nine laboratory technicians were
trained for their respective roles in the screening program.
Beginning in June 2013, standard meetings in Rwanda’s
15,000 villages informed community health workers of the
dates when a mobile team is planned to visit the health
center for screening.8 Concurrently, social mobilization
strategies including local radio broadcasts, church net-
works, and engagement with women’s groups were used to
raise cervical cancer awareness and educate women about
the upcoming availability of screening services. Community
health workers enrolled women for free screening and
nurses then reported to the district level on how many
reagents were needed and the length of time needed for
each screening day. Upon arriving for her screening, every
woman was informed on how samples will be collected.
Each woman was asked to stay at the health center for a few
hours to wait for her HPV test result.8 Beginning in Sep-
tember 2013, cervical cancer screening services became
available at Muhima, Rwinkwavu, Gahini, Butaro and
Ruhengeri District Hospitals, as well as 15 health centers
within the hospitals’ catchment areas. Altogether, this
geographic rollout brought coverage to a population of more
than 1.3 million people.
RESULTS
Between September 2013 and October 2014, a total of
7,520 women were tested through the screening program
(Table 1). The percentages of the female population that
received screening services during this time were 5.89%,
10.90%, 9.44%, 10.02%, and 1.01% in Muhima,
Rwinkwavu, Gahini, Butaro, and Ruhengeri district hos-
pitals, respectively. Of the 7,520 women tested, 874
(11.6%) women tested HPV-positive and 6,646 (88.4%)
were HPV-negative.
Of those 874 who screened positive, 780 (89%) received
VIA. The remaining 94 (11%) were lost to follow-up and did
not receive VIA. This includes 11 women from Muhima
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FIG 1. Algorithm for cervical cancer
screening and follow-up services.
HPV, human papillomavirus; LEEP,
loop electrosurgical excision proce-
dure; VIA, visual inspection with
acetic acid.
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83 women who were waiting for VIA after the data collection
period because of scheduling conflicts. Of the 780 women
who received VIA, 204 (26%) were VIA-positive, 561 (72%)
were VIA-negative, and 15 (1.9%) had suspected cancer
and were referred for biopsy. Eight of those 15 women
eventually underwent hysterectomy for treatment of ad-
vanced cervical cancer. Of the 204 women who were VIA-
positive, 151 received cryotherapy. In accordance with the
screening protocol, cryotherapy was administered on the
same day as VIA for the majority of patients. The remaining
53 cases had to be deferred to later dates because of
providers’ lack of comfort with the procedure or shortage of
cryotherapy gas. Notably, no patients underwent loop
electrosurgical excision in the first year of the program.
Overall, the careHPV test technology met the needs of this
screening program well, although several significant challenges
did arise. At times, inadequate infrastructure led to power
outages at Butaro, Gahini, and Rwinkwavu district hospitals.
This caused approximately 20% of the careHPV test runs to fail,
leading to waste of reagents and consumables. One of the 29
careHPV test systems used during the initial 12 months of
screening ceased functioning and had to be returned to the
manufacturer, reducing the efficiency of screening at the
Ruhengeri health center.
Delays in service provision and loss to follow-up were
caused by several factors. The 96-sample testing capacity
of the careHPV system (including six controls) occasionally
prevented same-day VIA and cryotherapy. Because the
collection of 90 samples in a single morning was not
feasible, some HPV-positive women were required to return
to the health facility for VIA and cryotherapy during a
second visit. Additional delays in the follow-up of HPV-
positive women for VIA occurred because of low availability
of trained providers. These barriers to providing same-day
follow-up were exacerbated by hesitancy among eligible
women to take advantage of screening services. To remedy
this, health facilities normalized the process by establishing
regular testing days at each center; this encouraged hesitant
patients to present to the health facilities for screening. After
the experience and testimony of those who were tested,
women came in mass requesting to be screened. Loss to
follow-up of HPV-positive women also occurred in the Kigali
area whenwomenwere not known or referred by community
health workers and contact information proved invalid.
DISCUSSION
To our knowledge, the data described here represent the
largest cohort to date of women screened for HPV through
DNA testing in an African country. The first year of
Rwanda’s National Cervical Cancer Screening and Treat-
ment Program succeeded in serving more than 7,000
women and referring more than 1,000 for further assess-
ment and care. Challenges included patient loss to follow-
up, lack of equipment and trained staff, and confidentiality
regarding HIV status. Our findings corroborate existing
literature in demonstrating that cervical cancer screening
using HPV DNA testing is both effective and feasible in low-
and middle-income settings.22–24 This is of particular im-
portance given that the global disease burden of cervical
cancer, a largely preventable disease, acts along socio-
economic lines, with nine of 10 deaths occurring in poor
countries.25 Global elimination of cervical cancer is in sight,
and Rwanda is leading the way in primary prevention
through HPV vaccination. However, comprehensive cer-
vical cancer programs that will make elimination a tangible
reality will also include screening, treatment, and palliation.
The WHO Global Strategy toward eliminating cervical
cancer as a public health problem recommends that
countries transition to HPV testing as the primary screening
method to reach this goal.26 This study demonstrates the
potential for success of expanded HPV screening in
Rwanda and other low-resource settings.
During the first 12 months of Rwanda’s cervical cancer
screening rollout across five districts, many precancerous
lesions were detected and treated and eight malignancies
were addressed. There is no doubt that many lives were
saved or extended by this program. This initial phase of
screening could not continue, however, because of dis-
ruptions in funding with theMoH’s partnership with Qiagen,
ultimately leading to a cancellation of the partnership after
the initial phase detailed here came to an end. The ex-
pected program rollout did not occur, and the expansion of
careHPV screening services is currently on hold. Currently,
screening for cervical cancer is done with Abbott molecular
HPV tests at five district hospitals (one per province). Other
health facilities are using VIA as a primary screeningmethod,
despite its lower sensitivity and specificity. The clear need
and health benefit that could be brought by reinstating this
comprehensive HPV screening program remain.
Prophylactic HPV vaccination is an effective cervical
cancer primary prevention strategy that has been imple-
mented with great success in Rwanda beginning in 2011.
However, the resulting reduction in cancer incidence will
not be appreciated for nearly 20 years,27 and the Gardasil
vaccine protects against only four (HPV 6, 11, 16, and 18)
of more than 100 known types of HPV.28 Because of these
TABLE 1. careHPV Sample Testing by District Hospital






Butaro 1,655 1,510 (91.2) 145 (8.8)
Gahini 1,587 1,425 (89.8) 162 (10.2)
Muhima 740 607 (82.0) 133 (18.0)
Ruhengeri 1,971 1,799 (91.3) 172 (8.7)
Rwinkwavu 1,567 1,305 (83.3) 262 (16.7)
Total 7,520 6,646 874
Abbreviation: HPV, human papillomavirus.
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limitations, vaccination campaigns must be coupled with
expanded screening and clinical services that accommo-
date all patients with cervical cancer, regardless of the
strain of their HPV infection or their stage at diagnosis.
Rwanda’s screening program with careHPV represents the
first time that healthcare providers have screened for
cervical cancer using a test that detects HPV DNA. Several
longitudinal studies have demonstrated that laboratory
testing for HPV DNA is more sensitive than both VIA and
cytology and is more effective in reducing CIN2 lesions and
cervical cancer mortality.11,29,30 It also predicts a longer
period of low risk of developing precancerous lesions,
allowing for screening intervals to be lengthened, an im-
portant programmatic element in developing countries
where many women face barriers to accessing health
centers. For these reasons, laboratory HPV testing is also
one of the most cost effective methods in resource-limited
settings.18,31,32 CareHPV test technology in particular is
practical for low-income settings as it does not require air
conditioning or running water and can be conducted by
those with very little lab experience.16 A limitation of the
careHPV test exemplified in this study is the need for a
batch of 96 samples (including six controls) for optimal
management of resources. Since collection of at least 90
samples in a single day was not always possible, some
women were required to return to the facility to receive their
result. Currently, technical innovations allowing for point-of-
care HPV testing exist but remain too costly for widespread
use in LMICs.33,34 However, the current WHO Global
Strategy for cervical cancer elimination stresses the im-
portance of market incentives to improve access to high
performance diagnostics such as HPV tests.34
Several considerable challenges arose during the imple-
mentation period. One issue that became immediately
apparent was the different age criteria for screening HIV-
negative and HIV-positive patients, which had the potential
to compromise patient privacy by inadvertently revealing
HIV status. These confidentiality concerns were addressed
through the revision of the age minimum for screening
services to 30 years for all women regardless of HIV status,
thereby ensuring that women with HIV receive the early
screening they require without jeopardizing the confiden-
tiality of their health history.
Additionally, a number of HPV-positive patients were lost to
follow-up because of the collection of inaccurate or in-
complete contact information, thereby preventing VIA and
other follow-up services from reaching these women.
Furthermore, as described above, same-day VIA was not
always possible, and the number of healthcare profes-
sionals trained in VIA was limited; these two factors com-
bined to create scheduling delays for follow-up
appointments. Even in cases in which same-day VIA was
provided, cryotherapy was not always administered im-
mediately following VIA because of a lack of necessary
resources or provider hesitancy. Once the high-coverage,
low-volume model of care was determined to be ineffective
for patient recruitment and service delivery, an alternative
focused coverage, high-volume model was adopted. Under
this new model, screening teams rotated among health
facilities and CHWs arranged for women from their re-
spective villages to attend screening services on pre-
determined days, thus increasing the efficiency of service
delivery at each location and reducing delays in care.
Standard practices were also amended to include verifying
patient contact information at the time of the first screening
visit to ensure that patients could be contacted for follow-up
appointments if necessary.
In addition to patient loss to follow-up, variable methods of
record keeping resulted in inconsistencies across the paper
recordsmaintained during the handover of samples between
testing and laboratory facilities. To ensure that all samples
were accounted for on both ends of these transactions, a
standard procedure for real-time count verification during
sample handover was implemented. Centrally driven quality
control oversight was established to ensure compliance,
adding a second layer of assurance. This mechanism of
regulatory oversight both empowered district hospitals by
granting ownership of their quality control practices and
establishing a standard of regulation through documented
consequences for inadequate performance.
Concerns regarding the efficient use and sustainable ac-
quisition of consumables posed a significant financial and
logistical challenge for the program. Assistance from the
Centers for Disease Control and Prevention was required to
procure a sufficient quantity of supplies within shelf life
requirements. Once acquired, efforts to reduce unneces-
sary waste occasionally led to delayed care for patients. As
no patients underwent loop electrosurgical excision pro-
cedure in the first year of the program, future cost con-
siderations must include the cost-efficiency of maintaining
this capacity at district hospitals.
In conclusion, the 12-month feasibility study conducted
from September 2013 to October 2014 demonstrates that
cervical cancer screening services using HPV testing
provided through public health facilities in Rwanda can be
successfully implemented and maintained in resource-
limited settings. Despite initial challenges—including
care provider training, patient hesitancy, loss to follow-
up, and financial and logistic challenges—the program
was executed successfully. In its first year of operation,
screening services were made available to thousands of
women who would not otherwise have received such care.
Although future studies will be required to determine the
population health impact and cost efficiency of the pro-
gram, the success observed in this HPV screening program
is promising of Rwanda’s ability to develop a robust, well-
informed cervical cancer screening program. Wider
implementation and scale-up of HPV testing throughout
Rwanda are recommended to reach the goal of cervical
cancer elimination.
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